Literature DB >> 30747357

Weight Loss Medications in the Treatment of Obesity and Hypertension.

Jordana B Cohen1,2, Kishore M Gadde3.   

Abstract

PURPOSE OF REVIEW: Weight loss is strongly associated with improvement in blood pressure; however, the mechanism of weight loss can impact the magnitude and sustainability of blood pressure reduction. RECENT
FINDINGS: Five drugs-orlistat, lorcaserin, liraglutide, phentermine/topiramate, and naltrexone/bupropion-are currently approved for weight loss therapy in the USA. Naltrexone/bupropion results in an increase in in-office and ambulatory blood pressure compared to placebo. Other therapies are associated with modest lowering of blood pressure, and are generally well-tolerated; nonetheless, evidence is limited regarding their effect on blood pressure, particularly longitudinally, in individuals with hypertension. Although weight loss medications can be an effective adjunct to lifestyle modifications in individuals with obesity, there is limited evidence regarding their benefit with regard to blood pressure. Future studies evaluating the effectiveness of weight loss medications should include careful assessment of their short- and long-term impact on blood pressure in individuals with hypertension.

Entities:  

Keywords:  Blood pressure; Hypertension; Obesity; Weight loss; Weight loss medication; Weight loss pharmacotherapy

Mesh:

Substances:

Year:  2019        PMID: 30747357      PMCID: PMC6415530          DOI: 10.1007/s11906-019-0915-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  13 in total

Review 1.  COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave.

Authors:  Ahmed A Kolkailah; Kayla Riggs; Ann Marie Navar; Amit Khera
Journal:  Curr Atheroscler Rep       Date:  2022-07-01       Impact factor: 5.967

Review 2.  Highlights of mechanisms and treatment of obesity-related hypertension.

Authors:  Elham Shams; Vijayvardhan Kamalumpundi; Joshua Peterson; Ronaldo Altenburg Gismondi; Wille Oigman; Marcelo Lima de Gusmão Correia
Journal:  J Hum Hypertens       Date:  2022-01-10       Impact factor: 2.877

Review 3.  Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Gland Surg       Date:  2020-02

4.  Phentermine-Induced Acute Kidney Injury Secondary to Uncontrolled Hypertension in a Patient with Weight Regain Post-bariatric Surgery.

Authors:  Marvin Wei Jie Chua; Boon Cheok Lai
Journal:  Obes Surg       Date:  2021-04-22       Impact factor: 4.129

5.  Blood Pressure-Lowering Therapy.

Authors:  Isabella Sudano; Elena Osto; Frank Ruschitzka
Journal:  Handb Exp Pharmacol       Date:  2022

6.  Long-term effects of weight-reducing drugs in people with hypertension.

Authors:  Andrea Siebenhofer; Sebastian Winterholer; Klaus Jeitler; Karl Horvath; Andrea Berghold; Cornelia Krenn; Thomas Semlitsch
Journal:  Cochrane Database Syst Rev       Date:  2021-01-17

7.  Growth hormone peak modifies the effect of BMI on increased systolic blood pressure in children with short stature.

Authors:  Yanying Li; Yanhong Zhang; Mei Zhang; Wanling Yang; Baolan Ji; Hui Pan; Bo Ban
Journal:  Sci Rep       Date:  2019-05-27       Impact factor: 4.379

8.  Obesity and resistant hypertension: Never ending story.

Authors:  Marijana Tadic; Cesare Cuspidi
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-26       Impact factor: 3.738

Review 9.  The limits and challenges of antiobesity pharmacotherapy.

Authors:  Kishore M Gadde; Katelyn D Atkins
Journal:  Expert Opin Pharmacother       Date:  2020-04-15       Impact factor: 3.889

10.  Pharmacophore Directed Screening of Agonistic Natural Molecules Showing Affinity to 5HT2C Receptor.

Authors:  Ganesh Kumar Veeramachaneni; V B S C Thunuguntla; Maharshi Bhaswant; Michael L Mathai; Jayakumar Singh Bondili
Journal:  Biomolecules       Date:  2019-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.